Please assess the completion status of the following clinical trial:

Trial Title: Cessation of Long-term Opioid Therapy in Chronic Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, age above 18.~* Chronic non-cancer pain (pain for 6 or more months, current pain not attributed to a cancerous disease).~* Referrals to the Massachusetts General Hospital (MGH) Center for Pain Medicine for opioid taper.~* Chronic (more than 3 months) prescription of morphine, oxycodone, hydrocodone, hydromorphone, codeine or any formulation of these medications.~* Morphine dose equivalent of 60 mg or above.~* Opioid treatment has to be stable (plus or minus20%) over the last 3 months.~* Meeting Substance Abuse and Mental Health Services Administration (SAMHSA) criteria for exit from chronic opioid therapy~* Willingness to taper and participate in treatment as randomized (including cognitive workshop sessions), able to meet the protocol follow-up schedule and activities~* Agreement to undergo random urine toxicology assays, which will be recommended to prescribing physician during study.~* Agreement to sign an opioid contract, as recommended to prescribing physician.~* Informed consent to study (IRB approved informed Consent form).~* English Language Literacy.~Exclusion Criteria:~* Methadone, suboxone or fentanyl patch: the tapering with these opioids would not be comparable to the other patients. As enrolment will be open during about 12 months, if a patient was motivated to participate in the study, they could be referred to the pain clinic for advice on a switch to a medication that could allow inclusion. They would, 3 months after this switch, become eligible for the study.~* Pregnancy.~* History of epilepsy and drug-induced seizures.~* Proof of current diversion of drugs or recent substance related legal problems (e.g. buying/selling on the streets).~* Concurrent use of illicit drugs and narcotics (urine toxicology), active diagnosis of substance abuse or dependence disorder within last 3 months.~* Absence of the prescribed drug in the urine toxicology~* Refusal of taper or dose reduction trial.~* Preference for suboxone or related treatments.~* Severe psychiatric condition and/or cognitive deficits limiting patient's ability to participate~* Involved in concurrent opioid management for an acute pain condition.~* Current suicidal ideation.~* Severe and unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological or hematological disease.~* General conditions that would impede participation in a group intervention, as assessed by evaluating physician (e.g. cognitive impairment, tendencies towards physical aggression).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy (CBT) (Type: EXPERIMENTAL): cognitive therapy (10 weekly sessions)
- no CBT- wait list (Type: NO_INTERVENTION): no cognitive therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).